Abstract
Lynch syndrome (LS) is an autosomal dominant disorder caused by a mutation in one of the mismatch repair genes. Mutation carriers have a life-time risk of developing colorectal cancer (CRC) of between 25 and 75 %. Since the importance of a centralized organization of surveillance was emphasized in the late 1980s, the number of registered LS families with a known mutation has increased enormously worldwide. Large-scale surveillance programs of these families have achieved a 62 % reduction in incidence of CRC and a 65–70 % decrease in mortality. Nevertheless, the risk of CRC is still substantial even when included in a program and the most optimal surveillance interval for gene carriers remains unknown. Hopefully, improvements in high quality colonoscopy and new endoscopic visualization techniques will further reduce CRC risk in those included in a surveillance program.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932
Aarnio M, Sankila R, Pukalla E et al (1999) Cancer risk in mutation carriers of DNA mismatch-repair genes. Int J Cancer 81:214–218
de Jong AE, Hendriks YM, Kleinbeuker JH et al (2006) Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130(3):665–671
Love RR, Morrissey JF (1984) Colonoscopy in asymptomatic individuals with a family history of colorectal cancer. Arch Intern Med 144:2209–2211
Mecklin JP, Jarvinen HJ, Aukee S, Elomaa I, Karjalainen K (1987) Screening for colorectal carcinoma in cancer family syndrome kindreds. Scand J Gastroenterol 22:449–453
Vasen HF, Hartog Jager FC, Menko FH, Nagengast FM (1989) Screening for hereditary non-polyposis colorectal cancer: a study of 22 kindreds in The Netherlands. Am J Med 86:278–281
Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411
Vasen HF, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, Offerhaus GJ, Meera KP (1995) Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 31A:1145–1148
Vasen HF, Nagengast FM, Khan PM (1995) Interval cancers in hereditary non-polyposis cololrectal cancer (Lynch syndrome). Lancet 345(8958):1183–1184
Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, de la Chapelle A, Mecklin JP (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834
de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, Vasen HF (2002) Surveillance for hereditary nonpolyposis: a long-term study on 114 families. Dis Colon Rectum 45:1588–1594
Mecklin JP, Aarnio M, Laara E et al (2007) Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 133(4):1093–1098
Vasen HF, Abdirahman M, Brohet R et al (2010) One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138(7):2300–2306
Engel C, Rahner N, Schulman K et al (2010) Efficacy of annual colonoscopic surveillance in individuals with hereditary non polyposis colorectal cancer. Clin gastroenterol Hepatol 8(2):174–182
Stuckless S, Green JS, Morgenstern M et al (2012) Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet 82(5):439–445
Vasen HF, Blanco I, Aktan-Collan K et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013 Feb 21 [Epub ahead of print]
Chai H, Brown RE (2009) Field effect in cancer—an update. Ann Clin Lab Sci 39:331–337
Enestvedt BK, Tofani C, Laine LA, Tierney A, Fennerty MB (2012) 4-Liter split dose polyethylene glycol is superior to other bowel preparations, based on systematic review and meta-analysis. Clin Gastroenterol Hepatol 10(11):1225–1231
Lai EJ, Calcerwood AH, Doros G et al (2009) The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc 69:620–625
Lynch HT, de la Chapelle A (1999) Genetic susceptibility to non polyposis colorectal cancer. J Med Genet 36:801–808
Huneburg R, Lammert F, Rabe C et al (2009) Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 41:316–322
Hurlstone DP, Karajeh M, Cross SS et al (2005) The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a propective “back-to-back” endoscopic study. Am J Gastroenterol 100:2167–2173
Stoffel EM, Turgeon DK, Stockwell DH et al (2008) Missed adenomas during colonoscopic surveillance in individuals with Lynch syndrome (hereditary non polyposis colorectal cancer). Cancer Prev Res 1:470–475
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Vos tot Nederveen Cappel, W.H., Järvinen, H.J., Lynch, P.M. et al. Colorectal surveillance in Lynch syndrome families. Familial Cancer 12, 261–265 (2013). https://doi.org/10.1007/s10689-013-9631-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-013-9631-1